Skip to content

Study · Randomized controlled trial · n = 50 · 2015

3 results

The effects of a course of intranasal oxytocin on social behaviors in youth diagnosed with autism spectrum disorders: a randomized controlled trial.

Guastella AJ, Gray KM, Rinehart NJ, Alvares GA, Tonge BJ, Hickie IB, Keating CM, Cacciotti-Saija C, Einfeld SL

Journal of child psychology and psychiatry, and allied disciplines2 Aug 2014Cited by 227 (Europe PMC)

PMID25087908 (opens in a new tab)DOI10.1111/jcpp.12305 (opens in a new tab)PepBankPUB-25087908
Publisher pagePubMedAsk about this study
Jump to 3 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study3

3 results from studies that gave the peptide. 3 results from people.

  1. 01HumanRandomized controlled trialEfficacy outcome

    In male youth aged 12 to 18 with autism spectrum disorder, an 8-week course of oxytocin nasal spray gave no benefit over placebo on the primary outcomes.

    In plain wordsIn boys and teens with autism, 8 weeks of oxytocin spray did not help social behavior more than placebo.

    Peptide
    Oxytocin
    Outcome
    No significant changePrimary outcomes (Social Responsiveness Scale, Clinical Global Impressions-Improvement)
    Study

    n = 50

    Comparator
    Placebo
    Analysis
    Primary
    Outcome group
    Cognition and memory · Mental health and mood
    Studied dose
    18 or 24 IU twice daily · intranasal · 8 weeksAs given in this study (human).

    Source sentences

    Summary
    Participants who received oxytocin showed no benefit following treatment on primary or secondary outcomes.
    2 context sentences
    Summary · context
    Primary outcomes were change in total scores on the caregiver-completed Social Responsiveness Scale and clinician-ratings on the Clinical Global Impressions-Improvement scale.
    Summary · context
    In a double-blind, placebo-controlled trial across two Australian university sites between February 2009 and January 2012, 50 male participants aged between 12 and 18 years, with Autistic or Asperger's Disorder, were randomized to receive either oxytocin (n = 26) or placebo (n = 24) nasal sprays (ei…
  2. 02HumanRandomized controlled trialEfficacy outcome

    In male youth with autism spectrum disorder, oxytocin gave no benefit over placebo on the secondary outcomes.

    In plain wordsIn boys and teens with autism, oxytocin spray did not improve other measured behaviors more than placebo.

    Peptide
    Oxytocin
    Outcome
    No significant changeSecondary outcomes (repetitive behaviors, developmental behaviors, social cognition)
    Study

    n = 50

    Comparator
    Placebo
    Analysis
    Secondary
    Outcome group
    Cognition and memory · Mental health and mood
    Studied dose
    18 or 24 IU twice daily · intranasal · 8 weeksAs given in this study (human).

    Source sentences

    Summary
    Participants who received oxytocin showed no benefit following treatment on primary or secondary outcomes.
    2 context sentences
    Summary · context
    Secondary assessments included caregiver reports of repetitive and other developmental behaviors and social cognition.
    Summary · context
    In a double-blind, placebo-controlled trial across two Australian university sites between February 2009 and January 2012, 50 male participants aged between 12 and 18 years, with Autistic or Asperger's Disorder, were randomized to receive either oxytocin (n = 26) or placebo (n = 24) nasal sprays (ei…
  3. 03HumanRandomized controlled trialSafety outcome

    In male youth with autism spectrum disorder, nasal sprays were well tolerated and oxytocin did not increase side effects compared with placebo.

    In plain wordsIn boys and teens with autism, oxytocin spray was well tolerated and caused no more side effects than placebo.

    Peptide
    Oxytocin
    Outcome
    No significant changeSide effects
    Study

    n = 50

    Comparator
    Placebo
    Outcome group
    Adverse events · Whole body
    Studied dose
    18 or 24 IU twice daily · intranasal · 8 weeksAs given in this study (human).

    Source sentences

    Summary
    Nasal sprays were well tolerated and there was no evidence of increased side effects resulting from oxytocin administration.
    1 context sentence
    Summary · context
    In a double-blind, placebo-controlled trial across two Australian university sites between February 2009 and January 2012, 50 male participants aged between 12 and 18 years, with Autistic or Asperger's Disorder, were randomized to receive either oxytocin (n = 26) or placebo (n = 24) nasal sprays (ei…

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Registered trials1

Trials this study reports on, or that list this study as a reference. Registry data from ClinicalTrials.gov.

1 trial · 1 completed · source ClinicalTrials.gov (opens in a new tab)

CompletedNot applicableNCT03114371

Oxytocin Intranasal Administrations in Children With Prader-Willi Syndrome Aged From 3 to 12 Years

University Hospital, Toulousen = 4028 Nov 2016 to 11 Jan 2019

Prader-Willi Syndrome

Trial pageClinicalTrials.govUpdated 12 Nov 2020

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    11 Oct 2026, 01:30 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 02:49 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.